{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-024427","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.734086+00:00","generated_at":"2026-06-01T03:22:09.101846+00:00","sec_items":["5.02","5.03","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Glucotrack appoints Andy Balo (ex-Dexcom EVP) to board; bylaws amended to lower quorum to one-third","bullets":["Appointed Andrew K. Balo, former Dexcom EVP of Clinical & Global Access, to board as independent director, effective June 14, 2024.","Balo brings 22 years at Dexcom, expertise in glucose monitoring regulatory submissions and clinical trials.","Board also amended bylaws to reduce shareholder quorum requirement from majority to one-third.","Balo will assist with upcoming human clinical studies for Glucotrack's implantable continuous blood glucose monitor.","Balo played critical role at Dexcom; his regulatory knowledge expected to aid Glucotrack's CBGM development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-024427","json":"https://secwatch.observer/filing/0001493152-24-024427.json","markdown":"https://secwatch.observer/filing/0001493152-24-024427.md","text":"https://secwatch.observer/filing/0001493152-24-024427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/0001493152-24-024427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:22:09.101846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5fe3b6bb2","claim":"Andrew K. Balo was appointed as independent board member at Glucotrack, Inc..","evidence_excerpt":"On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/0001493152-24-024427-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"independent board member"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}